Telormedix’ TMX-101 Commences Clinical Trial for Bladder Cancer
Telormedix announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive bladder cancer (NMIBC). TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.
The trial will be a Phase I/II, open-label, multicenter, dose escalation study which will consist of three parts. In the first part of the study, the safety and maximum tolerated dose (MTD) will be tested in patients with non-muscle-invasive bladder cancer (NMIBC) who have undergone a complete transurethral resection (TUR). TMX-101 will be administered once a week for a total of six instillations into the bladder of patients who have undergone TUR. The second part of the study will be an assessment of the effective biological dose in patients with one marker lesion remaining after TUR. Finally, the third part of the study will follow each of the patients to assess the safety of TMX-101 and the status of the disease within the first year. The study will be conducted in the Netherlands at four investigational sites and Telormedix anticipates that there will be a total of 21 to 30 patients.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
A Change of Culture for Healthcare

Molecule shown to repair damaged axons
Naturalpha launches a clinical investigation center for nutrition

Vitamin K prevents cell death - A new function for a long-known molecule
Medicyte GmbH Benefits From Multi-Million Euro EU Grant VascuBone

Biofilms - an invisible threat to food safety - Hotspots for biofilms

Scientists spread festive cheer as research reveals Christmas dinner can be healthy

Experimental therapy for immune diseases hits Achilles heel of activated T cells

Snake venom treatment investigated as antibiotic alternative for eye infections
Brief heat stress can have health benefits - Biologist Dr. Wenjing Qi from the University of Freiburg has discovered a genetic long-term effect in nematodes that influences the body’s stress response
